CN110167968B - 针对her3的抗原结合蛋白 - Google Patents

针对her3的抗原结合蛋白 Download PDF

Info

Publication number
CN110167968B
CN110167968B CN201780057182.8A CN201780057182A CN110167968B CN 110167968 B CN110167968 B CN 110167968B CN 201780057182 A CN201780057182 A CN 201780057182A CN 110167968 B CN110167968 B CN 110167968B
Authority
CN
China
Prior art keywords
her3
antigen
seq
binding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780057182.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167968A (zh
Inventor
罗兰·康特曼
丽莎·施米特
迈克·赫特
奥利弗·塞弗特
莫尼洛拉·奥莱奥耶
迈克尔·于斯特
斯蒂芬·迪尤贝尔
乔纳斯·赞特托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Stuttgart
Original Assignee
Universitaet Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Stuttgart filed Critical Universitaet Stuttgart
Publication of CN110167968A publication Critical patent/CN110167968A/zh
Application granted granted Critical
Publication of CN110167968B publication Critical patent/CN110167968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780057182.8A 2016-09-15 2017-09-15 针对her3的抗原结合蛋白 Active CN110167968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16188871 2016-09-15
EP16188871.4 2016-09-15
PCT/EP2017/073328 WO2018050848A1 (en) 2016-09-15 2017-09-15 Antigen binding protein against her3

Publications (2)

Publication Number Publication Date
CN110167968A CN110167968A (zh) 2019-08-23
CN110167968B true CN110167968B (zh) 2023-11-28

Family

ID=57017956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780057182.8A Active CN110167968B (zh) 2016-09-15 2017-09-15 针对her3的抗原结合蛋白

Country Status (13)

Country Link
US (1) US11008402B2 (https=)
EP (1) EP3512886B1 (https=)
JP (2) JP7203426B2 (https=)
KR (1) KR102469700B1 (https=)
CN (1) CN110167968B (https=)
AU (1) AU2017327769B2 (https=)
BR (1) BR112019005001A2 (https=)
CA (1) CA3033694C (https=)
DK (1) DK3512886T3 (https=)
ES (1) ES3037145T3 (https=)
MX (1) MX2019002664A (https=)
WO (1) WO2018050848A1 (https=)
ZA (1) ZA201901379B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019179627A1 (en) * 2018-03-22 2019-09-26 Universität Stuttgart Multivalent binding molecules
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022550316A (ja) * 2019-09-25 2022-12-01 ウニヴェルズィテート シュトゥットガルト 修飾ｅｈｄ２ドメインを含む結合モジュール
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
WO2022061256A2 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Egfr binding complex and method of making and using thereof
CN116133694B (zh) * 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
AU2023228226A1 (en) * 2022-03-03 2024-10-03 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Her3 binding protein and use thereof
CN115057946B (zh) * 2022-06-30 2023-05-16 四川省医学科学院·四川省人民医院 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用
KR20250161618A (ko) * 2023-03-17 2025-11-17 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-her3 및 항-met 항체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1650011A (zh) * 2002-03-26 2005-08-03 上海泽生科技开发有限公司 Erbb3用于肿瘤治疗的方法和组合物
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
CN104271761A (zh) * 2011-11-30 2015-01-07 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
MX358013B (es) 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
EP2912066A4 (en) 2012-10-25 2016-10-12 Sorrento Therapeutics Inc ANTIGENBINDING PROTEINS FOR BINDING ERBB3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1650011A (zh) * 2002-03-26 2005-08-03 上海泽生科技开发有限公司 Erbb3用于肿瘤治疗的方法和组合物
CN104271761A (zh) * 2011-11-30 2015-01-07 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin;GARNER,A.等;《CANCER RES.》;20131001;第73卷(第19期);第4-6页 *
靶向HER3逆转EGFR抑制剂耐药机制的研究进展;李真真等;《中国肿瘤》;20160605(第06期);全文 *

Also Published As

Publication number Publication date
ZA201901379B (en) 2024-06-26
KR20190065259A (ko) 2019-06-11
CA3033694A1 (en) 2018-03-22
US20190194350A1 (en) 2019-06-27
EP3512886A1 (en) 2019-07-24
AU2017327769B2 (en) 2023-12-21
JP7203426B2 (ja) 2023-01-13
KR102469700B1 (ko) 2022-11-23
JP2022169589A (ja) 2022-11-09
JP7638531B2 (ja) 2025-03-04
EP3512886B1 (en) 2025-06-11
AU2017327769A1 (en) 2019-03-07
WO2018050848A1 (en) 2018-03-22
CN110167968A (zh) 2019-08-23
CA3033694C (en) 2023-06-27
ES3037145T3 (en) 2025-09-29
JP2020501509A (ja) 2020-01-23
US11008402B2 (en) 2021-05-18
DK3512886T3 (da) 2025-08-18
BR112019005001A2 (pt) 2019-06-04
MX2019002664A (es) 2019-09-26

Similar Documents

Publication Publication Date Title
CN110167968B (zh) 针对her3的抗原结合蛋白
US20250295767A1 (en) Ror1-specific antigen binding molecules
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
JP6571527B2 (ja) 二重特異性抗体
JP2022545439A (ja) 新規ｉｌ－２１プロドラッグおよびその使用方法
Croasdale et al. Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
JP2021510521A (ja) Ｐｄ−１に対する単一ドメイン抗体及びその変異体
JP2025503402A (ja) Ｃｄｈ１７抗体及びがんを処置する方法
CN121758617A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
JP2022548728A (ja) 抗ｐｔｃｒａ抗体－薬物コンジュゲートおよびその使用
JP2026506762A (ja) 薬剤、方法、およびそれらの使用
CN119137148A (zh) 结合白蛋白的多肽及其用途
TW202304991A (zh) 穩定的多重特異性分子及其利用
CN120882866A (zh) Alpp特异性变体抗原结合分子
WO2025106822A2 (en) P2ry8 antibodies and methods of treating cancer
AU2024379016A1 (en) P2ry8 antibodies and methods of treating cancer
HK40108333A (zh) 双特异性抗体及使用方法
CN120271715A (zh) 抗体及其药物偶联物和用途
HK40120932A (zh) 抗体及其药物偶联物和用途
CN117794953A (zh) 双特异性抗体及使用方法
Duranti Novel molecular tools in cancer therapy: diagnostic and therapeutic applications of antibodies targeting ion channels and receptors.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Roland Contman

Inventor after: Lisa Schmidt

Inventor after: Huet Mickael

Inventor after: Oliver Seifert

Inventor after: Monilora Oleoye

Inventor after: Michael Hurst

Inventor after: Stephen Diubel

Inventor after: Jonas Zanterto

Inventor before: Roland Contman

Inventor before: Lisa Schmidt

Inventor before: Mike Hurt

Inventor before: Oliver Seifert

Inventor before: Monilora Oleoye

Inventor before: Michael Hurst

Inventor before: Stephen Diubel

Inventor before: Jonas Zanterto

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment